만성 손 습진(CHE) : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Chronic Hand Eczema (CHE) Market Outlook

Thelansis's "Chronic Hand Eczema (CHE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hand Eczema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Hand Eczema (CHE) Overview

Chronic Hand Eczema is a persistent inflammatory skin disorder driven by epidermal barrier dysfunction, immune dysregulation involving Th2 and Th1 pathways, and repeated exposure to irritants or contact allergens. It presents with erythema, vesicles, fissuring, hyperkeratosis, and pruritus predominantly affecting the dorsal hands and fingers, with occupational exposure frequently implicated. Diagnosis is clinical, supported by patch testing to identify contact sensitization; IGA scoring and disease duration reflect severity. Topical corticosteroids and emollients form first-line therapy; alitretinoin is indicated for refractory hyperkeratotic disease, and delgocitinib cream represents a newer topical JAK inhibitor option. Trigger avoidance and barrier protection are essential. Regular severity assessment guides escalation; occupational counseling and psychological support underpin quality-of-life management.

Key Highlights

• In Germany, diagnosed CHE cases are projected to increase from approximately 305,284 in 2025 to 337,306 by 2035.
• CHE remains a chronic inflammatory skin disorder associated with significant quality-of-life impairment and occupational burden.
• Persistent itching, pain, and skin barrier dysfunction continue to drive long-term disease burden.
• Treatment resistance and frequent disease recurrence remain key unmet clinical needs.
• Emerging targeted dermatology therapies are improving management options for moderate-to-severe disease.

Market Overview

• The France CHE market is projected to grow from approximately $155 MN to $420 MN by 2035.
• Market growth is supported by:
• Increasing adoption of advanced topical and systemic therapies
• Growing recognition and diagnosis of chronic disease cases
• Market expansion is driven by prolonged treatment duration and unmet therapeutic need.
• Future growth will depend on innovative targeted immunomodulatory treatments and personalized dermatology approaches.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Incyte Corporation
• LEO Pharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)